Journal of
Hematology & Oncology

ERRATUM

CrossMark

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Francine Foss[1*], Steven Horwitz[2], Barbara Pro[3], H. Miles Prince[4], Lubomir Sokol[5], Barbara Balser[6], Julie Wolfson[6] and Bertrand Coiffier[7]

Erratum

The original article [1] contains an error whereby Fig. 2a & b are mistakenly interchanged and contain incorrect colour-coding.

The correct versions of Fig. 2a & b are thus displayed below.

Author details
[1]Yale Cancer Center, 333 Cedar St, TMP 3, PO Box 208028, New Haven, CT 06520-8028, USA. [2]Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [3]Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. [4]Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. [5]Moffitt Cancer Center, Tampa, FL, USA. [6]Veristat, LLC, Southborough, MA, USA. [7]Hospices Civils de Lyon, Lyon, France.

Reference
1.   Foss F, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.

* Correspondence: francine.foss@yale.edu
[1]Yale Cancer Center, 333 Cedar St, TMP 3, PO Box 208028, New Haven, CT 06520-8028, USA
Full list of author information is available at the end of the article

BioMed Central

Foss *et al. Journal of Hematology & Oncology* (2017) 10:154

Page 2 of 2

Fig. 2: Survival based on clinical IRC assessment by best response to romidepsin (*n* = 130). Progression-free survival (**a**) and overall survival (**b**). Patients with insufficient efficacy data to determine response due to early termination (NE; *n* = 29) were included as nonresponders. *NE* not evaluable